TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in 10-year cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lipids profile, CRP, smear blood morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total antioxidative potential (TAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of endorphins and serotonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume ingested at maximum satiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Steady state gastric emptying rate (ml/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of postoperative cerebral hyperperfusion syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Ctrough and Area under the curve (AUC) of abacavir (ABC) and lamivudine (3TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participants' self-reported sexual behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: safety during endoscopic submucosal dissection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with ACC count of zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Improvement in VAS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in WOMAC Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal HO-1 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HO-1 protein level in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90 day Barthel Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascularization index of the endometrial region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of normotensive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Effect on Trough Forced Expiratory Volume in One Second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Optimum dose schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Step initiation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of menarche
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Abnormal Safety Laboratory Tests (ALT and/or Total Bilirubin) That Required Discontinuing Study Drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Undetectable HCV Virus 12 Weeks After Stopping Study Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Impact of containment on health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of patients needing Diazepam
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ankle Osteoarthritis Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pressure between the nasal tube and nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cell proliferation by Ki-67 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vaginal cuff recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Vrecruitable threshold (Vrec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of non-valvular atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of sarcoma on irradiated territory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: regional cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of cervical cancer biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual Analogue Scale (VAS) pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number retained in PrEP care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in Scott's Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Physical Activity levels through Accelerometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Physical Activity levels through the Godin Leisure-Time Exercise Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Physical Activity levels through the Abbreviated International Physical Activity Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip Harris Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg Length Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Treatment related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Resting Energy Expenditure (REE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evidence of Skin Change - Physician's Global Assessment (PGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evidence of Skin Change - PRP Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline to Week 8 on the SANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Serious Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Correctly Identified by SENSE With Hemorrhage Expansion (HE) or no Hemorrhage Expansion (NHE) Within 12 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total PCA Hydromorphone Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of DCFBC-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bio-availability of goserelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting at Least One A/California Influenza Event
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability of Imatinib
Endpoint domain: Adverse events/effects
Primary endpoint: hematologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cytogenetic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: molecular responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myasthenia Gravis Impairment Index Efficacy Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of local reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited systemic reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events during the whole study duration
Endpoint domain: Adverse events/effects
Primary endpoint: maximal tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lab parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in pulmonary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Local and Systemic Reactogenicity Events After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Local and Systemic Reactogenicity Events After Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Urine arsenic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in color and texture of burn scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Outcome of pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined diagnostic and treatment CPV® vignette domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck motion disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR50 response at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subcutaneous Echogenicity Grade (SEG) medial forearm (MFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subcutaneous Echo-Free Space Grade (SEFS) medial forearm (MFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subcutaneous tissue thickness measurement via ultrasound over medial forearm (MFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cardiac sympathetic activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in wear detected by optical scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Notable differences in pCLE images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of molecular relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hemoglobin Levels Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fibrinolytic factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cytoplasmic size increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative fentanyl requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of shoulder functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of shoulder pain
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to timing instructions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of organic dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fasting glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Laboratory safety assessments
Endpoint domain: Adverse events/effects
Primary endpoint: multiple-dose pharmacokinetics of MBX-2044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical safety and tolerability of MBX-2044
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose (MTD) of MBX-2044
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFR 4-5 days after Htx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total genomic sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iSARA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D patient reported outcome measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxford-12 patient reported outcome measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alcohol-related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Post prandial insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Argatroban Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of respiratory disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survey Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of clinical adverse events (tolerance)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sleep efficacy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in PDSS-2
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Systemic Glucose Disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Infusion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change of total score on IPSS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of photophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of corneal cystine crystals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hep C cAg levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Deep wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of 20-24 mg.h/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one year patency of the endovascular graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Termination of AVNRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Signs of oral lichen planus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interproximal Caries Zone of Radiolucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rates of adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rates of aetiology-confirmed meningitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean CNC Word Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BKB-SIN SNR-50 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Fully Completed at Least One ePRO
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of Differential Item Functioning (DIF) in Anxiety Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of Differential Item Functioning (DIF) in Depression Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients' perception of helpfulness in communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thrombotic event
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of oral squamous cell carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: PCR corrected adequate clinical and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of planned rIL-2 taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn Around Time to optimal treatment of septicemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reversal of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV Risk Events
Endpoint domain: Adverse events/effects
Primary endpoint: Progression rate of severe non proliferative diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Implanted Stents Meeting the Technical Success Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: area under the plasma-time curve from zero to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum olaparib concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach maximum plasma concentration for olaparib (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stem migration in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of renal dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Recovery Score (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to screening and risk-reducing behavior recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of ventilator-free days alive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Grafts Successfully Treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Identification of novel pathogenic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Adult Participants Achieving Clinical Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Response at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Remission at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase-2 Dose (RP2D)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal metabolism of Ampicillin and/or Gentamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cephalometric analysis measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissues measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Percent Fat at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving SLE Responder Index (SRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Who Maintain Weight or Experience Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Reporting one or More Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With TEAEs Leading to Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Average 0-10 NRS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of compliance to pharmacological treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of men who have sex with men, female sex workers and young women at high risk of HIV enrolled into a HIV combination prevention intervention package that includes PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention